HighVista Strategies LLC Buys New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

HighVista Strategies LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,364 shares of the biotechnology company’s stock, valued at approximately $374,000.

A number of other large investors also recently bought and sold shares of SRPT. Principal Securities Inc. acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth $26,000. Dimensional Fund Advisors LP increased its stake in Sarepta Therapeutics by 10.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 224,201 shares of the biotechnology company’s stock worth $21,621,000 after acquiring an additional 20,923 shares during the last quarter. Principal Financial Group Inc. increased its position in Sarepta Therapeutics by 125.3% during the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock worth $4,777,000 after purchasing an additional 27,549 shares in the last quarter. Norges Bank acquired a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $80,697,000. Finally, UBS Group AG grew its stake in Sarepta Therapeutics by 26.5% during the fourth quarter. UBS Group AG now owns 276,276 shares of the biotechnology company’s stock worth $26,641,000 after buying an additional 57,805 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

SRPT has been the subject of a number of research reports. Piper Sandler decreased their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Robert W. Baird lifted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, June 21st. BMO Capital Markets boosted their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research report on Monday, June 24th. Cantor Fitzgerald reissued a “neutral” rating and set a $152.00 price target on shares of Sarepta Therapeutics in a research report on Friday. Finally, UBS Group lifted their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $187.39.

Insiders Place Their Bets

In other news, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now owns 17,129 shares in the company, valued at $2,768,217.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Trading Up 0.1 %

Shares of NASDAQ SRPT opened at $127.21 on Monday. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25. The company has a market cap of $12.02 billion, a price-to-earnings ratio of 1,156.45 and a beta of 0.81. The business has a fifty day simple moving average of $137.26 and a 200-day simple moving average of $132.75.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same period last year, the company posted ($0.27) earnings per share. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. Sell-side analysts predict that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.